

BOTULINUM TOXIN FOR AXILLARY HYPERHIDROSIS

POLICY STATEMENT	COMMISSIONING POLICY
STATUS	NOT ROUTINELY COMMISSIONED
PROCEDURE/ TREATMENT	BOTULINUM TOXIN FOR AXILLARY HYPERHIDROSIS
ELIGIBILITY CRITERIA	<p>Botulinum toxin for axillary hyperhidrosis is not routinely commissioned by the CCG.</p> <p>Treatment may be considered on an exceptional basis for intractable, disabling focal primary hyperhidrosis when all of the following criteria are met:</p> <ul style="list-style-type: none"> • Topical aluminium chloride or other extra-strength antiperspirants are ineffective or result in a severe rash; AND • Iontophoresis has been ineffective; AND • Unresponsive or unable to tolerate pharmacotherapy prescribed for excessive sweating (e.g., anticholinergics) if sweating is episodic; AND • Significant disruption of life has occurred because of excessive sweating. <p>Exclusion</p> <p>The CCG will not commission botulinum toxin to treat hyperhidrosis in people with social anxiety disorder in line with The National Institute for Health and Care Excellence (NICE) clinical guideline CG159.</p> <p>NB. For approved requests the CCG will fund a maximum of 2 treatments per year per patient, not to be repeated more frequently than every 16 weeks.</p>
Date effective from	27 May 2021
Date published	15 June 2021

Review date	27 November 2021
Author	N/A (Taken from existing policies)
Clinical Reviewers	N/A (Taken from existing policies)
Approved by	Quality, Performance & Governance Committee
Responsible Officers	Chief Operating Officer, North Kirklees & Wakefield CCG NHS North Kirklees CCG & NHS Wakefield CCG GP Leads Planned Care
Reference	1. NICE CG159 - Social anxiety disorder: recognition, assessment and treatment